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Objective: To study associations of cerebrovascular metabolism genotypes and haplotypes with age
at Alzheimer’s disease dementia (AD) onset and with neuropsychiatric symptoms according to each
dementia stage.
Methods: Consecutive outpatients with late-onset AD were assessed for age at dementia onset
and Neuropsychiatric Inventory scores according to Clinical Dementia Rating scores, apolipoprotein E
gene (APOE) haplotypes, angiotensin-converting enzyme gene (ACE) variants rs1800764 and rs4291,
low-density lipoprotein cholesterol receptor gene (LDLR) variants rs11669576 and rs5930, cholesteryl
ester transfer protein gene (CETP) variants I422V and TaqIB, and liver X receptor beta gene (NR1H2)
polymorphism rs2695121.
Results: Considering 201 patients, only APOE-e4 carriers had earlier dementia onset in multiple
correlations, as well as less apathy, more delusions, and more aberrant motor behavior. Both ACE
polymorphisms were associated with less intense frontally mediated behaviors. Regarding LDLR
variants, carriers of the A allele of rs11669576 had less anxiety and more aberrant motor behavior,
whereas carriers of the A allele of rs5930 had less delusions, less anxiety, more apathy, and more
irritability. CETP variants that included G alleles of I422V and TaqIB were mostly associated with less
intense frontally mediated behaviors, while severely impaired carriers of the T allele of rs2695121 had
more anxiety and more aberrant motor behavior.
Conclusion: Though only APOE haplotypes affected AD onset, cerebrovascular metabolism geno-
types were associated with differences in several neuropsychiatric manifestations of AD.
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Introduction
Cerebrovascular risk factors play an important role in the
pathogenesis of Alzheimer’s disease dementia (AD). When
present in midlife, pooled cerebrovascular risk factors
synergistically increase AD risk and lower the age at AD
onset.1 As a result, these patients usually present with a
combination of AD and vascular neuropathological pro-
files.2 Conversely, we have previously shown that higher
cerebrovascular risk in late life leads to cognitive and
functional stabilization or even improvement for patients
with AD, possibly related to enhanced cerebral perfu-
sion,3 though some studies have shown that cerebrovas-
cular risk factors may lead to faster cognitive decline.2
The astrocyte-secreted apolipoprotein E is a cholesterol-
binding lipoprotein that transports cholesterol through cell
membranes4 and is involved in cholinergic dysfunction,5
atherogenesis, and amyloidogenesis,6 besides being a
high-affinity ligand for the low-density lipoprotein receptor
(LDLR) within the central nervous system.7 The apolipo-
protein E gene (APOE) is a moderately penetrant gene
that is neither a prerequisite nor a sufficient agent for
development of AD, despite the fact that APOE-e4 is the
most important genetic risk factor for incidence8 and earlier
onset of late-onset AD,1 while also affecting behavioral
performance2 and decreasing prospective physical activity
in such patients.3 APOE-e4 carriers are also more prone
to decreased risk of dementia associated with physical
activity,9 while neuropsychiatric assessment findings may
correlate with specific biomarkers.10
Several other genetic variants involved in cerebrovas-
cular metabolism have been associated with AD. The two
functional variants of the angiotensin-converting enzyme
gene (ACE) with the most significant effects for higher
activity and boosted serum levels of the angiotensin-
converting enzyme (ACE) are the promoter polymorphisms
rs1800764 and rs4291, affecting risk and age at onset
of the amnestic phenotype of AD,11 as well as cognitive
decline and incidence of early-onset hypertension.12 The
LDLR mediates increased astrocytic expression of APOE
induced by amyloid-b,4 whereas storage and release of
cholesterol depend on the expression of the low-density
lipoprotein receptor gene (LDLR), which resides within a
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region linked to AD in 19p13.3; rs116695767 and rs593013
are two of the most important genetic variants of the
epidermal growth factor precursor homology domain of
LDLR to be associated with disrupted cholesterol metabo-
lism and variability in the risk of AD. Cholesterol governs
synaptogenesis and myelin biosynthesis,14 while the cho-
lesteryl ester transfer protein (CETP) is associated with
reverse cholesterol transport (from tissues to the liver)5;
protective cholesteryl ester transfer protein gene (CETP)
variants lead to lower serum CETP levels and healthier
lipid profiles,15 though not all studies have shown gene-
tically mediated lifetime cognitive effects.16 Nevertheless,
the A allele of rs708272 (TaqIB) is associated with lower
serum CETP activity and lower coronary heart disease
risk,17 while the G allele of rs5882 (I422V) has been asso-
ciated with lower serum CETP levels and greater white
matter integrity in young adults,14 as well as with preserved
cognitive function in longevity18 and less medial temporal
lobe atrophy in APOE-e4 carriers with AD.19 Moreover, the
nuclear liver X receptor b (LXR-b) isoform is also expres-
sed in the brain,4 acting as a regulator of cholesterol
homeostasis, controlling amyloidogenesis, and modulating
inhibition of angiotensin II, while several variants of the
LXR-b gene (NR1H2) close to APOE in chromosome 19
have also been linked with variable risk of AD.20
We aimed to examine associations of genetic variants
of APOE, ACE, LDLR, CETP, and intron 2 of NR1H2 with
age at onset of late-onset AD and with neuropsychiatric
symptoms, stratified by stage of dementia.
Methods
Participants
In this cross-sectional study, consecutive outpatients with
late-onset AD according to U.S. National Institute on Aging-
Alzheimer’s Association criteria21 were recruited from the
Setor de Neurologia do Comportamento, Hospital São
Paulo, Universidade Federal de São Paulo (UNIFESP),
São Paulo, SP, Brazil, from October 2010 to February
2013. All outpatients with this diagnosis who were followed
during the study period were recruited. Late-onset AD was
defined as AD with onset of dementia syndrome after
age 60 years.1 All patients underwent magnetic resonance
imaging (MRI) to evaluate either medial parietal or medial,
basal, or lateral temporal atrophy or, in cases of claus-
trophobia or pacemaker use, a computed tomography (CT)
scan to exclude vascular lesions. Patients with history of
stroke were not included in the study.
A detailed self-report and/or proxy report was con-
ducted for assessment of age at AD onset, years of school-
ing, gender, and history of antipsychotic and antidepressant
therapy. Information on age at dementia onset was obtained
through a review of medical records and confirmed
after an interview with the caregiver (preferably a family
member), who was required to visit the patient frequently.
The time of onset of subjective memory complaints or
mild cognitive impairment was not taken into account;
rather, only the time of dementia onset (when functional
decline actually began) was considered. Use of antipsy-
chotics or antidepressants was quantified in patients who
had been receiving them for at least 3 months before the
evaluation, to ensure that proper clinical response result-
ing from stability of drug levels in the central nervous
system had been achieved, as well as because follow-up
assessments at the study facility are usually conducted in
3-month intervals.
Neuropsychiatric assessment
A thorough neuropsychiatric evaluation was conducted,
with particular attention to caregiver-reported Clinical Demen-
tia Rating (CDR)22 and the 10-item version of the Neuro-
psychiatric Inventory, which does not take into account
night-time behavior disturbances or appetite and eating
abnormalities.23 Effects of body mass index on age at AD
onset1 and cognitive and functional change3 have been
previously assessed in our population, and associations of
sleep duration and sleep satisfaction with neuropsychiatric
symptoms and APOE haplotypes have been described
elsewhere.24 Ratings for the final score of each item in the
Neuropsychiatric Inventory took into account the frequency
and severity of each patient’s behaviors, while the total
score was the sum of the subscale scores. All functional
and behavioral assessments were conducted on weekday
mornings, by the same examiner (FFO).
Genotyping procedures
Blood samples were collected from all patients into tubes
containing 0.1% ethylenediaminetetraacetic acid (EDTA).
Genomic DNA was extracted from these samples using
a standard salting-out procedure for determination of APOE
haplotypes (polymorphisms rs7412 and rs429358), ACE
genotypes and haplotypes (polymorphisms rs1800764 and
rs4291), LDLR genotypes and haplotypes (polymorphisms
rs11669576 and rs5930), CETP genotypes and haplotypes
(polymorphisms rs5882 and rs708272), and genotypes of
rs2695121 (intron 2 of the NR1H2 gene). All single nucle-
otide polymorphisms (SNPs) were assessed by real-time
polymerase chain reactions using TaqMan® SNP Geno-
typing Assays on the Applied Biosystems® 7500 Fast Real-
Time PCR System (Applied Biosystems®, Carlsbad, USA).
Standard manufacturer protocols were followed. Geno-
typing procedures were carried out only after clinical data
had been collected from all patients, thus ensuring observer
blinding to genetic data.
Outcome measures
Primarily, we sought to determine associations of genetic
variants of APOE, ACE, LDLR, CETP, and intron 2 of the
LXR-b gene NR1H2 with age at AD onset and neuro-
psychiatric symptoms, stratified by dementia stage. Sec-
ondarily, we also investigated combined associations of
gender and schooling with age at AD onset, as well as
associations of gender, schooling, age at dementia onset,
antipsychotic therapy, and antidepressant therapy with
each neuropsychiatric symptom according to CDR scores.22
Finally, frequencies and scores for all behavioral symp-
toms were compared according to stage of dementia.
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Statistical analysis
Associations of APOE haplotypes, ACE genotypes and
haplotypes of rs1800764 and rs4291, LDLR genotypes
and haplotypes of rs11669576 and rs5930, CETP geno-
types and haplotypes of rs5882 and rs708272, and
genotypes of rs2695121 with age at AD onset were
investigated independently by way of the Mann-Whitney
U test and further assessed in combination in a multiple
linear regression model that included male gender and
schooling as covariates. Multiple linear regression models
including a copy of each minor allele, each copy of APOE-e4,
male gender, years of schooling, age at dementia onset,
antipsychotic therapy, and antidepressant therapy were
employed at each dementia stage to investigate associa-
tions of these factors with each behavioral symptom and
with Neuropsychiatric Inventory total scores. Each haplo-
type that was represented in at least three patients
was associated with each behavioral symptom and with
Neuropsychiatric Inventory total scores at each dementia
stage by the Mann-Whitney U test. The threshold of signifi-
cance was set at p o 0.05.
Ethical considerations
This study is part of a larger research project (1067/10)
approved by the Ethics Committee of Hospital São Paulo,
UNIFESP, in August 2010 (CAAE 0540.0.174.000-10). All
invited patients and their legal representatives agreed to
participate in the study and provided written informed
consent before the evaluation.
Results
At the end of the recruitment period, 217 patients had
been included. Of these, 16 (7.4%) were excluded due to
missing genetic information, resulting in a final sample of
201 patients.
Table 1 shows demographic and clinical results for the
final sample. More than two-thirds of patients were female,
47 patients (23.4%) received antipsychotic treatment, and
85 (42.3%) were on at least one antidepressant.
Table 2 reports genotypes and haplotypes for the final
sample. Overall, 108 patients (53.7%) were APOE-e4
carriers, while 93 (46.3%) were APOE-e4 non-carriers.
All assessed genetic variants were in Hardy-Weinberg
equilibrium.
Regarding independent haplotypes that could affect
age at dementia onset, we found that APOE-e4/e4 car-
riers had earlier dementia onset by 4.31 years (p = 0.001),
rs5882-AA/rs708272-AG carriers had later dementia
onset by 1.77 year (p = 0.048), rs5882-AG/rs708272-AA
carriers had earlier dementia onset by 4.55 years
(p = 0.014), and rs11669576-GG/rs5930-GG carriers had
later dementia onset by 2.14 years (p = 0.021). The only
isolated genotype that affected age at AD onset was
rs5882-AA: carriers had later dementia onset by 1.76 year
(p = 0.018), but this analysis did not survive multiple
correlations. According to Table 3, the only variable to
affect age at AD onset in a multiple linear regression
model was the APOE haplotype: each copy of APOE-e4
led to earlier dementia onset by 1.728 year (p = 0.012).
Tables 4, 5, and 6 show the results of multiple linear
regression analyses regarding factors that may affect
Table 1 Demographic and clinical profile (n=201)
Assessed factors n (%) Mean 6 SD Range
Gender
Female 141 (70.1) - -
Male 60 (29.9) - -
Age at dementia onset (years) - 73.5366.3 60.0-88.0
Schooling (years) - 4.2263.7 0-15
Neuropsychiatric Inventory score (0-120 points) - 22.11616.3 0-87
Antipsychotic therapy (mg/day)
Olanzapine 1 (0.5) 10.0060.0 10-10
Quetiapine 36 (17.9) 70.83674.5 25-400
Risperidone 10 (5.0) 1.9060.9 1.0-4.0
Antidepressant therapy (mg/day)*
Amitriptyline 1 (0.5) 25.0060.0 25-25
Bupropion 8 (4.0) 150.0060.0 150-150
Citalopram 18 (9.0) 23.3367.7 20-40
Clomipramine 1 (0.5) 25.0060.0 25-25
Escitalopram 3 (1.5) 10.0060.0 10-10
Fluoxetine 11 (5.5) 27.27610.1 20-40
Mirtazapine 2 (1.0) 30.0060.0 30-30
Nortriptyline 1 (0.5) 10.0060.0 10-10
Paroxetine 8 (4.0) 27.50614.9 20-60
Sertraline 25 (12.4) 60.00620.4 50-100
Trazodone 9 (4.5) 61.11622.0 50-100
Venlafaxine 3 (1.5) 175.006114.6 75-300
*Overall, 85 patients (42.3%) used antidepressants during the evaluation, five of whom were on two antidepressants at the same time:
one took bupropion 150 mg/day + trazodone 50 mg/day, one took citalopram 20 mg/day + mirtazapine 30 mg/day, and three took sertraline
50 mg/day + trazodone 50 mg/day.
SD = standard deviation.
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each behavioral symptom and Neuropsychiatric Inventory
total score for patients who were mildly impaired (CDR =
1.0), moderately impaired (CDR = 2.0), and severely
impaired (CDR = 3.0), respectively. Overall, Neuropsy-
chiatric Inventory total scores increased according to
dementia severity. For mildly impaired patients (n=78),
anxiety was the most frequent and highest-scored symp-
tom, while euphoria was the least frequent and hallucina-
tions were the lowest-scored symptom. For moderately
impaired patients (n=92), apathy was the most frequent
and the highest-scored symptom, while euphoria was the
least frequent and hallucinations were the lowest-scored
symptom. For severely impaired patients (n=31), apathy
was the most frequent and highest-scored symptom,
while euphoria was the least frequent and lowest-scored
symptom.
Considering associations of independent haplotypes
with behavioral scores in mildly impaired patients,
rs1800764-CC/rs4291-AT carriers (n=10) had more
hallucinations (1.4062.6 versus 0.1560.4, p=0.031),
rs1800764-CT/rs4291-AA carriers (n=11) had more dis-
inhibition (1.0061.3 versus 0.3961.3, p=0.021) and more irri-
tability (3.0064.1 versus 1.1263.0, p=0.022), rs1800764-TT/
rs4291-AA carriers (n=19) had more agitation (3.3263.1
versus 1.6963.1, p=0.017), rs11669576-AG/rs5930-AG
carriers (n=5) had more apathy (7.2063.6 versus
3.1963.7, p=0.026), rs11669576-AG/rs5930-GG carriers
(n=8) had less apathy (1.0062.1 versus 3.7363.8,
p=0.033), rs5882-AA/rs708272-AG carriers (n=14) had
lower Neuropsychiatric Inventory total scores (9.866
6.7 versus 18.66611.3, p=0.007) and less irritability (0.576
0.8 versus 2.8063.1, p=0.008), rs5882-AA/rs708272-GG
carriers (n=13) had higher Neuropsychiatric Inventory total
scores (24.3869.4 versus 15.62611.0, p=0.007) and more
apathy (5.3163.4 versus 3.0863.8, p=0.041) and more
dysphoria (3.3863.8 versus 1.3462.2, p=0.036), rs5882-AG/
rs708272-GG carriers (n=12) had less anxiety (1.4262.7
versus 4.3964.5, p=0.025), and rs5882-GG/rs708272-AG
carriers (n=5) had more delusions (3.4065.1 versus
0.5861.7, p=0.027).
Table 2 Genetic analysis findings (n=201)
Genotypes and haplotypes n (%) p-value*
APOE haplotypes
e4/e4 23 (11.4) -
e4/e3 78 (38.8) -
e4/e2 7 (3.5) -
e3/e3 83 (41.3) -
e3/e2 10 (5.0) -
e2/e2 0 (0.0) -
rs1800764 genotypes








rs1800764 CC/rs4291 AA 7 (3.5) -
rs1800764 CC/rs4291 AT 20 (10.0) -
rs1800764 CC/rs4291 TT 26 (12.9) -
rs1800764 CT/rs4291 AA 31 (15.4) -
rs1800764 CT/rs4291 AT 62 (30.9) -
rs1800764 CT/rs4291 TT 0 (0.0) -
rs1800764 TT/rs4291 AA 55 (27.3) -
rs1800764 TT/rs4291 AT 0 (0.0) -
rs1800764 TT/rs4291 TT 0 (0.0) -
rs11669576 genotypes (LDLR8)








rs11669576 AA/rs5930 AA 0 (0.0) -
rs11669576 AA/rs5930 AG 0 (0.0) -
rs11669576 AA/rs5930 GG 2 (1.0) -
rs11669576 AG/rs5930 AA 0 (0.0) -
rs11669576 AG/rs5930 AG 10 (5.0) -
rs11669576 AG/rs5930 GG 17 (8.5) -
rs11669576 GG/rs5930 AA 23 (11.4) -
rs11669576 GG/rs5930 AG 85 (42.3) -
rs11669576 GG/rs5930 GG 64 (31.8) -
rs2695121 genotypes (NR1H2 gene)
CC 76 (37.8) 0.691
CT 93 (46.3)
TT 32 (15.9)
rs5882 genotypes (CETP gene)
AA 75 (37.3) 0.412
AG 100 (49.8)
GG 26 (12.9)
rs708272 genotypes (CETP gene)




rs5882 AA/rs708272 AA 3 (1.5) -
rs5882 AA/rs708272 AG 38 (18.9) -
rs5882 AA/rs708272 GG 34 (16.9) -
rs5882 AG/rs708272 AA 11 (5.5) -
rs5882 AG/rs708272 AG 56 (27.8) -
rs5882 AG/rs708272 GG 33 (16.4) -
rs5882 GG/rs708272 AA 7 (3.5) -
rs5882 GG/rs708272 AG 12 (6.0) -
rs5882 GG/rs708272 GG 7 (3.5) -
ACE = angiotensin-converting enzyme gene; APOE =
apolipoprotein E gene; CETP = cholesteryl ester transfer protein
gene; LDLR = low-density lipoprotein cholesterol receptor gene;
NR1H2 = liver X receptor beta gene.
*Hardy-Weinberg equilibrium (chi-square test).
Table 3 Multiple linear regression for age at AD onset
(n=201)
95%CI
Effects b Lower Upper p-value
Constant 75.099 72.513 77.686 o 0.001
Male gender -1.473 -3.419 0.472 0.137
Years of schooling 0.134 -0.113 0.381 0.285
Copies of APOE-e4 -1.728 -3.071 -0.385 0.012
Copies of rs1800764-C 0.608 -1.119 2.335 0.488
Copies of rs4291-T 0.310 -1.502 2.122 0.736
Copies of rs11669576-A -1.177 -3.562 1.207 0.331
Copies of rs5930-A -1.251 -2.601 0.099 0.069
Copies of rs2695121-T 0.745 -0.516 2.006 0.246
Copies of rs5882-G -0.668 -2.039 0.703 0.338
Copies of rs708272-A -0.530 -1.963 0.902 0.466
F-ratio = 2.044; multiple R = 0.312; adjusted squared multiple
R = 0.050; p = 0.031.
95%CI = 95% confidence interval; AD = Alzheimer’s disease
dementia; APOE = apolipoprotein E gene.
Results in bold are significant.
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Considering associations of independent haplotypes
with behavioral scores in moderately impaired patients,
rs1800764-CC/rs4291-AT carriers (n=8) had less agitation
(0.3760.7 versus 2.7663.5, p=0.018), rs11669576-AG/
rs5930-GG carriers (n=7) had less apathy (2.0064.5
versus 5.0564.5, p=0.049), rs11669576-GG/rs5930-AA
carriers (n=8) had less anxiety (0.1260.4 versus 2.686
3.9, p=0.033), rs11669576-GG/rs5930-AG carriers (n=42)
had less irritability (3.2663.7 versus 1.7662.6, p=0.034),
rs11669576-GG/rs5930-GG carriers (n=30) had less
irritability (1.3762.4 versus 2.9763.4, p=0.006), rs5882-AG/
rs708272-AA carriers (n=8) had more agitation (4.7562.9
versus 2.3563.4, p=0.008) and more hallucinations
(3.0063.8 versus 0.8961.9, p=0.018) and more disinhibition
(4.0065.3 versus 1.0862.5, p=0.029), and rs5882-AG/
rs708272-AG carriers (n=23) had less agitation (1.3962.9
versus 2.9463.5, p=0.012).
Considering associations of independent haplotypes
with behavioral scores in severely impaired patients,
rs1800764-CT/rs4291-AA carriers (n=3) had more aber-
rant motor behavior (9.3362.3 versus 3.1464.6, p=0.033),
rs1800764-CT/rs4291-AT carriers (n=11) had less disin-
hibition (1.2762.9 versus 3.3564.0, p=0.038), rs1800764-TT/
rs4291-AA carriers (n=12) had more disinhibition (4.2564.5
versus 1.5862.8, p=0.029), rs5882-AA/rs708272-AG car-
riers (n=5) had more anxiety (8.0065.7 versus 2.3563.6,
p=0.023), rs5882-AG/rs708272-AG carriers (n=11) had
more irritability (6.0964.1 versus 2.3063.6, p=0.028), and
rs5882-AG/rs708272-GG carriers (n=8) had less delu-
sions (0.2560.5 versus 3.0063.9, p=0.017).
Discussion
With the exceptions of anxiety and irritability, a trend was
found for all other behavioral symptoms to be intensified
according to functional decline; likewise, most significant
correlations were found in later dementia stages. Anxiety
is usually inversely correlated with apathy,25 whereas overall
neuropsychiatric symptoms tend to correlate better with
functional independence than with cognitive decline.25,26
Antipsychotic therapy was associated with higher Neu-
ropsychiatric Inventory total scores for mildly impaired
patients, particularly regarding disinhibition, and with more
delusions and more agitation for moderately impaired
patients, probably representing the need for psychotropic
treatment when more behavioral symptoms are present,
while agitation does not usually improve with atypical
antipsychotics in the long term.26 Likewise, antidepressant
therapy was associated with higher Neuropsychiatric
Inventory total scores for mildly impaired and severely
impaired patients (particularly regarding dysphoria), and
with more agitation for moderately impaired patients, also
representing the expected need for such therapy accord-
ing to symptoms of depression.
Male gender was associated with more irritability in
mildly impaired patients, more apathy in moderately
impaired patients, and higher Neuropsychiatric Inven-
tory total scores, particularly regarding delusions, in
severely impaired patients. Gender differences have been
reported in other studies, particularly regarding greater



































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Rev Bras Psiquiatr. 2017;39(2)
100 FF de Oliveira et al.
Schooling did not correlate with dementia onset in
this sample. Nevertheless, more years of education were
associated with less dysphoria in moderately impaired
patients and with lower Neuropsychiatric Inventory total
scores in severely impaired patients, particularly regard-
ing agitation and irritability. Though an earlier study
showed that educational attainment and AD duration
did not affect behavior,25 patients were not stratified by
dementia stage, and some associations may have been
missed. Education enhances cognitive reserve and may
affect the way the brain copes with the burden of AD
neuropathology, thus modulating behavior.
Later dementia onset was associated with fewer hal-
lucinations, less euphoria, and less apathy for moderately
impaired patients. Considering that hallucinations are
strong predictors of faster functional decline,26 they may
also be more frequent when dementia starts earlier.
A high prevalence of hallucinations and extrapyramidal
signs might predict the presence of Lewy bodies in
patients with AD.27 In severely impaired patients, later
dementia onset was associated with higher Neuropsy-
chiatric Inventory total scores, particularly regarding dis-
inhibition, but also with less apathy and less aberrant
motor behavior, a complex link that could be partly due to
APOE-e4 non-carriers having later AD onset.
On analysis of multiple correlations, only APOE hap-
lotypes affected the age at dementia onset in this sample,
confirming the essential role of genetically mediated
neurodegeneration on AD onset.1 Furthermore, mod-
erately impaired APOE-e4 carriers had less apathy,
whereas severely impaired APOE-e4 carriers had more
delusions and more aberrant motor behavior. Whereas
some cross-sectional studies have not found associations
of APOE haplotypes with specific neuropsychiatric symp-
toms25 or sleep satisfaction,24 other studies have shown
dose-dependent associations of copies of APOE-e4 with
delusions,28 aberrant motor behavior,6 anxiety,29 and
agitation.30 Mechanisms involve atrophy of the prefrontal
cortex,29 temporal lobe hypoperfusion,28 cholinergic
imbalance,6 and tau-mediated disruption of frontal ser-
otonergic and dopaminergic networks.30 APOE haplo-
types have also been associated with variable frequency
of hallucinations.6,28 The incidence of delusions and hal-
lucinations tends to be dissociated, considering that in AD
delusions are usually more common than hallucinations,
while in Lewy body dementia syndromes, hallucinations
are more common than delusions.31 Though APOE-e4
carrier status seems to predispose to late-onset depres-
sion,3 particularly in women,32 we did not find correlations
with dysphoria in our sample. Nevertheless, one study
showed that women have earlier AD onset when they are
APOE-e4 carriers with a history of depression,33 confirm-
ing that gender differences might affect dementia onset.
Considering ACE genotypes, carriers of the C allele of
rs1800764 had more hallucinations when mildly impaired
and less dysphoria when moderately impaired, whereas
carriers of the T allele of rs4291 had less dysphoria when
severely impaired. Regarding represented haplotypes
in independent analyses, presence of the C allele of
rs1800764 was associated with less agitation, while
presence of the A allele of rs4291 was associated with
more agitation, more disinhibition, more irritability, and worse
aberrant motor behavior. To the best of our knowledge,
these are all previously unreported associations, while only
the T allele of rs4291 was reported as a susceptibility factor
for unipolar major depression and hypothalamic-hypophy-
seal-adrenocortical axis hyperactivity in an earlier study of
subjects without dementia.34 Given that angiotensin-con-
verting enzyme degrades amyloid-b35 and is overexpressed
in a compensatory manner in the hippocampus, frontal
cortex, and caudate nucleus of both hemispheres of patients
with AD,12 suppression of frontally mediated behaviors
could occur by boosted enzyme levels and activity. Func-
tional studies are needed to confirm these associations.
Considering LDLR genotypes, carriers of the A allele of
rs11669576 had less anxiety and more aberrant motor
behavior when moderately impaired, whereas carriers
of the A allele of rs5930 had less delusions when mildly
impaired, less anxiety when moderately impaired, and
higher Neuropsychiatric Inventory total scores when severely
impaired, particularly regarding apathy and irritability.
Regarding represented haplotypes in independent ana-
lyses, presence of the G allele of rs5930 was asso-
ciated with less apathy in mildly and moderately impaired
patients. Still, carriers of rs11669576-GG/rs5930-GG had
later dementia onset. The A allele of rs11669576 has been
associated with variable risk of AD, either increasing risk
when in combination with copies of APOE-e47 or decreas-
ing risk - only in women - when in combination with other
LDLR polymorphisms,36 while the A allele of rs5930
was associated with lower risk of AD when combined with
other LDLR polymorphisms in an earlier study.13 Although
neuropsychiatric symptoms have not previously been
studied in association with variants of LDLR, genotypes
associated with less AD neuropathology36 could lead to
later dementia onset and milder behavioral burden in
earlier stages.
Considering CETP genotypes, carriers of the G allele of
rs5882 had more delusions when mildly impaired, less
dysphoria when moderately impaired, and less anxiety
when severely impaired, whereas carriers of the A allele
of rs708272 had higher Neuropsychiatric Inventory total
scores when severely impaired, particularly regarding
delusions, anxiety, and aberrant motor behavior. Regard-
ing represented haplotypes in independent analyses,
mildly impaired carriers of rs5882-AA/rs708272-GG had
higher Neuropsychiatric Inventory total scores, particu-
larly regarding apathy and dysphoria, whereas moder-
ately impaired carriers of rs5882-AG/rs708272-AA had
more agitation, more hallucinations, and more disinhibi-
tion. Carriers of rs5882-AG/rs708272-AG had less agita-
tion when moderately impaired and more irritability
when severely impaired. Carriers of rs5882-AA had later
dementia onset, but this finding did not survive multiple
correlations; conversely, carriers of rs5882-AG/rs708272-
AA had earlier dementia onset on independent analysis.
Though associations of CETP genotypes with behavioral
symptoms have not been reported before, the AA geno-
type of rs708272 was associated with increased risk of
AD for APOE-e4 carriers in one meta-analysis,37 while the
GG genotype of rs5882 has been associated either with
slower cognitive decline and lower risk of AD,15 with faster
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cognitive decline and higher risk of AD,38 or with increased
risk of AD only for APOE-e4 non-carriers.39 The G allele
of rs708272 and the G allele of rs5882 seemed to play
protective roles in our sample, possibly by improving
myelin biosynthesis in the brain.
Severely impaired carriers of the T allele of rs2695121
had more anxiety and more aberrant motor behavior.
Among all polymorphisms of the LXR-b gene (NR1H2),
the T allele of rs2695121 is the most significant for risk of
AD,20 though it had not been previously associated with
behavioral symptoms. Polymorphisms in cellular choles-
terol efflux-related genes may affect the neuropsychiatric
profile of patients with AD, as increased cholesterol levels
induce amyloidogenesis.
An important limitation of this study is that it was con-
ducted in a single center with no randomization. We tried
to mitigate this drawback by ensuring that examiners were
blinded to genetic data during the evaluations. In addition,
the genotype and haplotype frequencies found were similar
to those reported in most previous studies, confirming that
our outpatient sample was probably representative of
our population as a whole. The cross-sectional design of
this study precludes deeper assumptions regarding causal
relations. Even though APOE haplotypes were the only
genetic factors to consistently affect age at AD onset,
variants involved in cerebrovascular metabolism were
associated with several behavioral symptoms, leading to
the conclusion that cerebrovascular risk plays an important
genetically mediated role in neuropsychiatric manifesta-
tions of AD.
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